If you haven`t bought my first call:
or the second one:
Then you should know that the recent deal with the United Kingdom’s national single-payer health...
This play looks tempting ngl. NASDAQ:BNGO
Bionanon made very tasty returns so why not return. Price is near 0+/- ATR in keltner and if it closes above I will enter.
Last time I entered around $5 and avg'ED up till $5.6.
Took Profit around $14 but this chart looks promising.
Genomics is still an underrated sector and there are many supporters of its hot...
ARKG looks like a double bounce at the bottom of thee channel, which is also the 0.382 retracement of the wave 4. Probably a little bit more channeling here before we get going.
If we get a reversal here, wave 5 should bring us to anywhere between 145-160 by EoY
Here is my follow up update on original CRSP swing short trade idea I put up on January 14th.
On this post, I am zooming out to weekly chart, looking at longer time frame to capture cyclical trends.
Going back all the way to 2017 inception period, the higher than average volatilities are pretty easy to notice. It moves up really fast but also coming down. Every...
EDIT NASDAQ:EDIT is a genome editing company with treatments being developed for Leber congenital amaurosis**, Usher syndrome, neurological diseases, Sickle cell disease, beta-thalassemia, as well as cancer treatments through NK cells. The leber congenital amaurosis clinical trial is currently the furthest along but still in its earlier stages but has completed...
The short volume ratio is decreasing which means good news for us. - Fintel
Also looks like it's time for a reversal on the 1HR MACD so we could be in for a breakout with a high upside. All I'm hearing is nothing but good news associated with Bionano Genomics.
However, we cannot fail to ignore the declining revenues every year. Keep an eye on this till the next...
Technical Analysis
Since early December, we have had over a dozen tails on the purple up-trend arrow drawn in.
The 50sma is now coming into play, as a break below that, could take us another 20% down to the 100sma.
An appropriate level to exit the trade then, would be below the 50sma.
There also horizontal support as we fill the gap.
Important Note:...
BNGO PT
Q1 25$
Q2 35$
Q3 50$
Q4 75$
2022 120$
2023 300$
Once in a lifetime oppurtunity don't miss out, genomics will be the leading sector in market gains.
One of my favourite ETFs at the moment.
Cup and handle formed a while back. Still bullish imo.
I am long on this. Will add on dips.
Im Cathie Wood we trust.
Did $ARKG just put in a short term top? $97 bound.
C-Dub fans - please don't hate on me. This Eth is going to $200+ eventually but could use a ABC correction.
Start loading in the $90s if we see it.
Atara Biotherapeutics , Inc. (Nasdaq: ATRA ), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases
"Atara made significant progress in 2020 and is well-positioned for a strong 2021," said...
BNGO (Bionano Genomics) is forming a textbook bull flag. This comes on the heels of a share offering, which is important. Share offerings dilute the value of the stock in the short term, but if general sentiment remains bullish, provides a buying opportunity for a takeoff after the retracement. Well, now we also have a bullish continuation pattern in the form of a...
$BNGO can go ahead and hit $10 real quick.
Your comments are welcome.
##############
Legal disclaimer: I am not a financial advisor. The advice here given is not a financial advice even though my excitement might make it look like such. This account shouldn't be followed by anyone expecting something from me. You trade at your own risk and nobody can guarantee...
This was my first buy signal at 0.82usd, when i saw that volume coming:
and then the second buy signal at 1.18:
Now i think a retracement is in cards, because...
